11.8 C
London

C

C

Bayer antibody-drug conjulate (ADC) misses in phase 2 mesothelioma trial

Bayer antibody-drug conjulate (ADC) misses in phase 2 mesothelioma trial
Bayer's antibody-drug conjulate (ADC) anetumab ravtansine has failed to show improvements in the survival rates of mesothelioma patients. Stock prices of Bayer's collaborators ImmunoGen and MorphoSys declined as the announcement was made. Malignant pleural mesothelioma is a rare cancer that affects more than 25,000 people around the world. Around 15,000 new cases are seen every...

WHAT IS MESOTHELIOMA AND WHO MIGHT BE AT RISK?

WHAT IS MESOTHELIOMA AND WHO MIGHT BE AT RISK?
Mesothelioma is a type of cancer which usually grows in the pleural membrane in the side of the chest. The chest contains two layers, the pleural space, which are both as thin as the skin of a balloon. The layers, known as the pluera or pleural membrane, line the outside of the lung (inner...

LATEST